Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Gilead Sciences, Inc. — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.59, while Gilead Sciences, Inc. trades at $133.34 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| EMB | GILD | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $155.80 |
52-Week Low | $91.59 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.54, down slightly by 0.03% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include scheduled dividends for 2026, with payouts of $0.41 and $0.40 per share. News highlights focus on emerging market bond risks and Federal Reserve policy impacts, with the ETF showing a 12% total return over the past year but only 1% year-to-date gains as of May 2026.
The outlook for EMB is cautious due to bearish technical indicators and macroeconomic sensitivities. Key risks include emerging market sovereign default exposure and interest rate volatility. Analyst sentiment is mixed, with attention on Fed policy and global bond market dynamics as critical drivers for future performance.
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
